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ORIGINAL ARTICLE
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BACKGROUND Despite treatment with effective antimalarial drugs, the mortality rate is still high in severe cases of the 
disease, highlighting the need to find adjunct therapies that can inhibit the adhesion of Plasmodium falciparum-infected 
erythrocytes (Pf-iEs).
OBJECTIVES In this context, we evaluated a new heparan sulfate (HS) from Nodipecten nodosus for antimalarial activity and 
inhibition of P. falciparum cytoadhesion and rosetting.
METHODS Parasite inhibition was measured by SYBR green using a cytometer. HS was assessed in rosetting and cytoadhesion 
assays under static and flow conditions using Chinese hamster ovary (CHO) and human lymphatic endothelial cell (HLEC) cells 
expressing intercellular adhesion molecule-1 (ICAM1) and chondroitin sulfate A (CSA), respectively.
FINDINGS This HS inhibited merozoite invasion similar to heparin. Moreover, mollusk HS decreased cytoadherence of P. 
falciparum to CSA and ICAM-1 on the surface of endothelial cells under static and flow conditions. In addition, this glycan 
efficiently disrupted rosettes.
CONCLUSIONS These findings support a potential use for mollusk HS as adjunct therapy for severe malaria.
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Plasmodium falciparum accounts for most cases of se-
vere and lethal malaria, causing 435,000 deaths per year, 
especially in children under five years old.(1) Malaria af-
fects approximately 25% of pregnant women living in ma-
laria endemic regions and is responsible for up to 20% of 
maternal deaths.(1) Although several factors contribute to 
the virulence of this species, binding of P. falciparum-in-
fected erythrocytes (Pf-iEs) to the vascular endothelium 
(cytoadherence) plays a major role.(2) In addition, Pf-iEs 
can also adhere to infected (auto-agglutination) and unin-
fected erythrocytes (rosetting). These events may lead to 
occlusion of the microvasculature of vital organs, contrib-
uting to the pathogenesis of severe malaria.(2,3)
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Although current malaria therapy kills parasites 
quickly, it has already been shown that non-viable Pf-
iEs retain the ability to cytoadhere in the first 24 h after 
administration of drugs, including artesunate,(4) which 
probably contributes to the high mortality observed in 
the first hours of hospital admission even after the rec-
ommended treatment.(5) Based on this, the use of adjunct 
therapies has been proposed. Due to its anticoagulant 
properties, heparin was used in the past as adjunctive 
treatment for severe malaria, but its use is hindered by 
side effects, including bleeding events.(6) Previous stud-
ies have shown that other sulfated polysaccharides with 
improved safety profiles are also able to prevent cytoad-
herence of P. falciparum to several host receptors, in-
hibit merozoite invasion, and disrupt rosettes.(7,8,9,10)
Previously, we described a new heparan sulfate (HS) 
isolated from the mollusk bivalve Nodipecten nodosus. 
This unique HS is formed by repeating disaccharide units 
of β-d-glucuronic acid 1→4 N-acetyl-α-d-glucosamine 
containing a rare sulfation pattern on carbon 2 or 3 of the 
glucuronic acid units [Supplementary data (Fig. 1)]. The 
mollusk glycan exhibits antithrombotic activity without 
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inducing bleeding. Furthermore, experiments in vivo 
demonstrated that HS attenuates hematogenous metas-
tasis, thrombosis and inflammation.(11,12) Here, we have 
examined the antimalarial activity of this compound and 
its effects on adhesion to the host receptors chondroitin 
sulfate A (CSA) and intercellular adhesion molecule-1 
(ICAM-1), as well its ability to disrupt rosettes.
MATERIALS AND METHODS
Mollusk HS - Several specimens of the marine mol-
lusk N. nodosus were kindly provided by the Instituto de 
Ecodesenvolvimento da Baía da Ilha Grande ― IEDBIG 
(Rio de Janeiro state, Brazil) and used for extraction of HS. 
The HS purification protocol was described elsewhere.(11)
Parasite culture and growth inhibition - Rosetting 
FCR3S1.2 and non-rosetting FCR3 strains were culti-
vated in fresh type O+ human erythrocytes with com-
plete parasite medium and kept at 37ºC in 5% CO2 and 
5% O2.
(13) To achieve a synchronous culture, consecutive 
treatments with a 5% solution of d-sorbitol were applied 
at 48-h intervals. The effects of mollusk HS on specific 
stages of P. falciparum development was assessed by 
growth inhibition assay.(14) Briefly, after synchroniza-
tion, young trophozoites (~ 24-h old) or ring forms (~ 
3-h old) were incubated in 96-well plates with different 
concentrations of mollusk HS or heparin for 24 h or 48 
h. After incubation, parasite growth inhibition was mea-
sured by SYBR green using a cytometer.
Static cytoadhesion assay - FCR3 parasites that ad-
hered to ICAM1 (Pf-iEsICAM-1) or CSA (Pf-iEsCSA) were 
selected by panning on Chinese hamster ovary (CHO)-
ICAM1 or human lymphatic endothelial cells (HLECs) 
cells, respectively, as described before.(7) Then, Pf-iEsCSA 
and Pf-iEsICAM-1 were incubated over confluent HLEC or 
CHO-ICAM1 monolayers for 1 h alone or in the presence 
of several concentrations of HS. After extensive washing 
to remove non-adherent Pf-iEs, the slides were fixed and 
stained with Giemsa, and the percentage inhibition rela-
tive to a control was determined under the microscope.(7)
Flow-based cytoadhesion assay - The ability of the 
mollusk HS to desequester Pf-iEs was assessed using 
flow-based cytoadhesion assays, as described previous-
ly.(15) Briefly, 5 × 105 Pf-iEsCSA were added to the culture 
slides and allowed to cytoadhere statically. After 1 h, 
culture slides were mounted in a flow chamber system 
through which cytoadhesion medium (control) or HS 
(100 µg/mL) was passed under different shear stresses. 
The remaining Pf-iE adherents were counted in 30 ran-
domly chosen fields.
Rosetting assay - FCR3S1.2 parasites were treated 
with different concentrations of mollusk HS or heparin 
at 37ºC for 1 h. Parasite medium was used as control. 
Then, parasites were stained with acridine orange and 
the rosetting formation was determined under a micro-
scope. A rosette was scored when a parasitized cell was 
bound to at least two non-infected erythrocytes.(8)
Statistical analysis - Statistical significance was 
determined using one-way analysis of variance or Stu-
dent’s t test for parametric data. Kruskal-Wallis and post 
hoc tests or Mann-Whitney’s U test were used for non-
parametric data. All statistical analyses were performed 
using Prism version 5.02 (GraphPad, USA), and values 
were considered significant when p < 0.05.
RESULTS AND DISCUSSION
Effects of mollusk HS on P. falciparum growth - To 
evaluate the antimalarial activity of the mollusk HS, 
we analyzed P. falciparum growth for 48 h using the 
fluorescence-based SYBR green assay. Like heparin, 
the mollusk HS inhibited parasite growth in a dose-
dependent manner (Fig. 1A). To investigate whether the 
mollusk HS inhibited merozoite invasion or intracellular 
parasite development, synchronized ring-stage parasites 
were cultured for 24 h in the presence of the mollusk HS. 
As shown in Fig. 1B, ring maturation rates were not sig-
nificantly reduced even at the highest HS concentration 
(1000 µg/mL). On the other hand, when synchronized 
late-stage forms were incubated with the mollusk HS, 
a significant decrease in parasite count was observed 
compared with untreated controls at 24 h after treatment 
(Fig. 1C). This result suggests that mollusk HS blocked 
merozoite invasion (or schizont rupture) in a dose-de-
pendent manner and reached up to 91% inhibition at the 
highest dose (1000 μg/mL). It has been demonstrated 
that growth inhibition of P. falciparum by other sulfated 
polysaccharides, such as heparin, sulfated fucans, and 
fucosylated chondroitin sulfate, is due to inhibition of 
invasion of red blood cells by merozoites.(7,9) The exact 
Fig. 1: mollusk heparan sulfate (HS) inhibits Plasmodium falciparum growth and merozoite invasion. Ring synchronized P. falciparum-infected 
erythrocytes (A and B) or late-stage forms (trophozoites) (C) cultured at 0.8% parasitemia and 2% hematocrit were incubated at 37ºC for 48 h 
(A) or 24 h (B and C) with increasing concentrations of mollusk HS or heparin. The percentage of growth inhibition was calculated relative to 
control values (parasites were grown in RPMI 1640 medium), and the results are expressed as the means ± SD of triplicates. *p < 0.05; ***p < 
0.001 (Kruskal-Wallis and Dunn’s post hoc test).
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mechanisms by which these compounds could affect 
merozoite invasion are still unclear, although a study has 
shown that heparin binds to several erythrocyte-binding 
P. falciparum proteins, including ligand molecules that 
are essential for moving junction complex formation.(16)
Effects of mollusk HS on P. falciparum adhesion in-
teractions - Currently, intravenous artesunate is recom-
mended as the first-line therapy for patients with ma-
laria complications. The pathologic hallmark of severe 
P. falciparum malaria is the sequestration of parasitized 
erythrocytes in various tissues due to interactions medi-
ated mainly by P. falciparum erythrocyte membrane pro-
tein 1 (PfEMP-1) with several host receptors on endothe-
lial (cytoadhesion) or normal red blood cells (rosetting). 
Importantly, in vitro cytoadherence of Pf-iEs continues 
for several hours after parasite death by antimalarials as 
a result of slow degradation of PfEMP-1 on the surface 
of Pf-iEs,(4) which suggests that the high mortality after 
hospital admission despite effective treatment may be 
due to this persistent parasite adhesion. Therefore, the 
use of adjunct therapies is urgently needed.
Here, we selected FCR3 parasites for a CSA- or 
ICAM-1-binding phenotype. CSA is mostly expressed in 
placental trophoblasts and is an important receptor for se-
questration of Pf-iEs, which seems to be a key feature in 
the pathogenesis of placental malaria.(17) In turn, the role 
of ICAM1 in the sequestration of Pf-iEs in the microvas-
culature of other organs, such as the brain, remains elu-
sive, probably due to the high number of host receptors 
involved in parasite adhesion. However, there is abundant 
evidence that supports a critical role of this receptor as-
sociated with disease severity (as reviewed in(18)).
Based on the ability of heparin and other glycocon-
jugates in inhibiting P. falciparum cytoadhesion to en-
dothelial cells and rosette formation, we evaluated the 
effects of the mollusk HS on parasite adhesion events 
in three ways. (i) We showed that HS inhibited cytoad-
herence even at the lowest dose tested (1 µg/mL), and 
reached 86% and 100% inhibition of Pf-iEsCSA (Fig. 2A) 
and Pf-iEsICAM-1 (Fig. 2B), respectively, at the highest 
dose (1000 µg/mL); (ii) having demonstrated the ability 
of HS to inhibit the cytoadherence of Pf-iEs under static 
conditions, we investigated whether the compound was 
able to reverse cytoadhesion of Pf-iESCSA to HLECs un-
der flow conditions. As shown in Fig. 2C, 100 µg/mL HS 
significantly reversed Pf-iEsCSA adhesion compared with 
controls for all shear stresses tested. Only 4.1% ± 2.6% 
of parasites remained attached to HLECs at the high-
est shear stress, a reduction of approximately 10× com-
pared with controls (41.1% ± 15.2%); (iii) finally, after 
demonstrating that mollusk HS is capable of preventing 
parasite binding under static and flow conditions, the ef-
fects of the compound on rosette disruption was inves-
tigated. We found that HS dose dependently disrupted 
rosettes, and at two high doses (100 and 1000 µg/mL), 
rosette formation was inhibited by approximately 100% 
relative to control. As shown in Fig. 3, HS disrupted ro-
settes at a rate similar to heparin. This rosette-disrupting 
activity was comparable with that reported for other sul-
fated polysaccharides, such as fucosylated chondroitin 
sulfate and curdlan sulfate.(9,10) Indeed, it is well known 
that many glycosaminoglycans, including heparin and 
heparan sulfate, bind to the DBL1α domain of PfEMP-1, 
the major ligand involved in endothelial cytoadhesion, 
which can contribute to rosette formation.(19)
Fig. 2: the effect of mollusk HS on cytoadhesion of Plasmodium falciparum. Cytoadhesion of FCR3 strain after incubation of chondroitin sulfate 
A (CSA)- (A) or intercellular adhesion molecule-1 (ICAM1)-binding (B) P. falciparum-infected erythrocytes (Pf-iEs) with different concentra-
tions of heparan sulfate (HS) is shown under static conditions. Mollusk HS is also capable of reversing binding of Pf-iEsCSA on human lymphatic 
endothelial cells (HLECs) under flow conditions with increasing shear stress (C). Data are expressed as percentages relative to control. Data are 
representative of three independent assays with error bars indicating ± SD. *p < 0.05; ***p < 0.001 (Kruskal-Wallis and Dunn’s post hoc test).
Fig. 3: mollusk heparan sulfate (HS) and heparin disruption of Plas-
modium falciparum rosettes after incubation for 1 h is shown at the 
indicated concentrations of each compound. Data are expressed as 
percentages relative to control (no compound). Data are shown as the 
mean of two independent experiments with error bars indicating ± 
SD. Glycosaminoglycans (GAG).
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In conclusion - Here, we showed that HS from the 
bivalve mollusk N. nodosus effectively inhibited the de-
velopment of the P. falciparum asexual blood stages in 
vitro. In addition, the mollusk HS disrupted rosetting and 
cytoadherence of Pf-iEs to CSA and ICAM-1 receptors 
expressed on endothelial cells, similar to heparin. The 
reversion of cytoadhesive phenotypes to ICAM-1, CSA, 
and rosetting is a desirable feature because these pheno-
types are related to the severity of the malaria. Recently, 
it was shown that mollusk HS inhibited P-selectin activ-
ity,(12) which can function as a receptor for PfEMP-1(20) 
and is known to contribute to malaria pathogenesis.(3) 
Despite displaying comparable activity to heparin, HS 
does not cause relevant bleeding. Previously, we showed 
that mollusk HS has reduced anticoagulant activity com-
pared with porcine heparin. Doses up to 10 mg/kg did not 
induce bleeding in rats or changes in plasma-activated 
partial thromboplastin times.(11) The unique structural 
feature of mollusk HS relies on the presence of signifi-
cant amounts of O-sulfate groups in glucuronic acid 
and glucosamine residues, not frequently found in their 
mammalian counterparts. No 3-O-sulfated glucosamine 
residues were detected, backing the observation that mol-
lusk HS shows low antithrombin. This peculiar structure 
is unique in animal phyla and suggests the occurrence of 
sulfotransferases in the bivalve, with different substrate 
specificities of those observed in mammalians.(11,12)
However, there is no information about the effects of 
mollusk HS in humans. In our cytotoxicity assay, mollusk 
HS demonstrated no effect against non-infected eryth-
rocytes at any concentration tested [Supplementary data 
(Fig. 2)], but a previous study showed reduced viability 
(by 35%) of BHK-21 (baby hamster kidney) cells in vitro 
at 100 µg/mL.(11) Overall, the present study contributes to 
identification of a new heparin analog potentially useful 
as a safe adjunctive therapy for severe malaria.
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